First off, Rey and Bourbon, Biogen does not get any Anavex stock; it is not a stock swap. As to liquidity, cash will flow with the royalty payments, which might begin in 2018.
A deal with Biogen brings awareness to Anavex' pipeline and other firms/institutions will readily be willing to join forces and handle the R&D work on the other drugs.
Actually, having a boatload of cash on the balance sheet makes Anavex more attractive to other firms than if it were Biogen stock, which will appreciate in value with the line-up of 2-73, 3-71 et al.
Market Data 
Markets 
AI
